You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alten R, Hochberg MC, Cohen RB, et al
SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data
Annals of the Rheumatic Diseases 2013;72:A624.